Rubius Therapeutics to Present at Jefferies Virtual 2020 Healthcare Conference
Rubius Therapeutics (Nasdaq: RUBY) announced that CEO Pablo J. Cagnoni, M.D. will engage in a fireside chat at the Jefferies Virtual 2020 Healthcare Conference on June 2, 2020, at 1:00 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Rubius Therapeutics (Nasdaq: RUBY) announced that CEO Pablo J. Cagnoni, M.D. will engage in a fireside chat at the Jefferies Virtual 2020 Healthcare Conference on June 2, 2020, at 1:00 p.m. ET. The session will focus on the company's development of a new class of cellular medicines known as Red Cell Therapeutics™, aimed at treating cancer and autoimmune diseases. A live audio webcast of the event will be available on the company’s website, along with an archived replay for 90 days post-event.
Details
News Market Reaction – RUBY
The recorded move for RUBY in the trading session of this news was +2.01%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that Pablo J. Cagnoni, M.D., chief executive officer, will participate in a fireside chat at the Jefferies Virtual 2020 Healthcare Conference on Tuesday, June 2, 2020, at 1:00 p.m. ET.
A live audio webcast will be available on the Events and Presentations page within the Investors and Media section of the Rubius Therapeutics website. An archived replay will be accessible for 90 days following the event.
About Rubius Therapeutics
Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. For more information, visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us on Facebook.
Contacts:
Lori Melançon
Vice President, Corporate Affairs
+1 (617) 949-5296
lori.melancon@rubiustx.com
Media Contact:
Dan Budwick
1AB
+1 (973) 271-6085
dan@1abmedia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.